Serotonin-norepinephrine reuptake inhibitor

(Redirected from SNRI)
Jump to: navigation, search

WikiDoc Resources for

Serotonin-norepinephrine reuptake inhibitor

Articles

Most recent articles on Serotonin-norepinephrine reuptake inhibitor

Most cited articles on Serotonin-norepinephrine reuptake inhibitor

Review articles on Serotonin-norepinephrine reuptake inhibitor

Articles on Serotonin-norepinephrine reuptake inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Serotonin-norepinephrine reuptake inhibitor

Images of Serotonin-norepinephrine reuptake inhibitor

Photos of Serotonin-norepinephrine reuptake inhibitor

Podcasts & MP3s on Serotonin-norepinephrine reuptake inhibitor

Videos on Serotonin-norepinephrine reuptake inhibitor

Evidence Based Medicine

Cochrane Collaboration on Serotonin-norepinephrine reuptake inhibitor

Bandolier on Serotonin-norepinephrine reuptake inhibitor

TRIP on Serotonin-norepinephrine reuptake inhibitor

Clinical Trials

Ongoing Trials on Serotonin-norepinephrine reuptake inhibitor at Clinical Trials.gov

Trial results on Serotonin-norepinephrine reuptake inhibitor

Clinical Trials on Serotonin-norepinephrine reuptake inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Serotonin-norepinephrine reuptake inhibitor

NICE Guidance on Serotonin-norepinephrine reuptake inhibitor

NHS PRODIGY Guidance

FDA on Serotonin-norepinephrine reuptake inhibitor

CDC on Serotonin-norepinephrine reuptake inhibitor

Books

Books on Serotonin-norepinephrine reuptake inhibitor

News

Serotonin-norepinephrine reuptake inhibitor in the news

Be alerted to news on Serotonin-norepinephrine reuptake inhibitor

News trends on Serotonin-norepinephrine reuptake inhibitor

Commentary

Blogs on Serotonin-norepinephrine reuptake inhibitor

Definitions

Definitions of Serotonin-norepinephrine reuptake inhibitor

Patient Resources / Community

Patient resources on Serotonin-norepinephrine reuptake inhibitor

Discussion groups on Serotonin-norepinephrine reuptake inhibitor

Patient Handouts on Serotonin-norepinephrine reuptake inhibitor

Directions to Hospitals Treating Serotonin-norepinephrine reuptake inhibitor

Risk calculators and risk factors for Serotonin-norepinephrine reuptake inhibitor

Healthcare Provider Resources

Symptoms of Serotonin-norepinephrine reuptake inhibitor

Causes & Risk Factors for Serotonin-norepinephrine reuptake inhibitor

Diagnostic studies for Serotonin-norepinephrine reuptake inhibitor

Treatment of Serotonin-norepinephrine reuptake inhibitor

Continuing Medical Education (CME)

CME Programs on Serotonin-norepinephrine reuptake inhibitor

International

Serotonin-norepinephrine reuptake inhibitor en Espanol

Serotonin-norepinephrine reuptake inhibitor en Francais

Business

Serotonin-norepinephrine reuptake inhibitor in the Marketplace

Patents on Serotonin-norepinephrine reuptake inhibitor

Experimental / Informatics

List of terms related to Serotonin-norepinephrine reuptake inhibitor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant used in the treatment of clinical depression and other affective disorders. They are also sometimes used to treat anxiety disorders, obsessive-compulsive disorder, attention deficit hyperactivity disorder (ADHD) and chronic neuropathic pain. They act upon two neurotransmitters in the brain that are known to play an important part in mood, namely, serotonin and norepinephrine. This can be contrasted with the more widely-used selective serotonin reuptake inhibitors (SSRIs), which act only on serotonin.

Mode of action

Activity on norepinephrine reuptake is thought necessary for an antidepressant to be effective on neuropathic pain, a property shared with the older tricyclic antidepressants but not with the SSRIs.

Depression is thought to be caused by a lack of information flow between neurons in certain parts of the brain. Neurons pass information to each other by means of chemicals known as neurotransmitters, which shoot across the tiny synapses between the cells. After firing, most of the neurotransmitter is reabsorbed by the presynaptic cell in a process called reuptake.

Antidepressants work by increasing the number of neurotransmitters active in the synapse, thereby enhancing neuronal activity and increasing the responsiveness of mood. Modern antidepressants usually achieve this effect by blocking the transporter proteins that reabsorb certain neurotransmitters, hence the name "reuptake inhibitors".

SNRIs were developed more recently than SSRIs, and there are relatively few of them. Their efficacy as well as their tolerability appears to be somewhat better than the SSRIs, owing to their compound effect.

Adverse effects

As with the SSRIs, abrupt discontinuation of SNRI-medication usually leads to a discontinuation syndrome which could include states of anxiety and further symptoms. It is therefore recommended to slowly taper down the dose under the supervision of a psychopharmacologist when discontinuing SNRIs. Due to the effects on increasing Norepinephrine synaptic activity, these drugs are contraindicated in patients with hypertension, heart disease, or risk of stroke.

SNRIs currently available

  • venlafaxine (tradenames Effexor XR®, Effexor®) is the first and most commonly used SNRI. Although it also works on dopamine somewhat at high dosages, the majority of its effect is on serotonin and norepinephrine.
  • desvenlafaxine (tradename Pristiq®) is the active metabolite of venlafaxine and is believed to work in the same manner. It will be introduced by Wyeth in late 2007-early 2008.
  • nefazodone (tradename Serzone®) is an antidepressant with efficacy similar to SSRIs, but without the sexual side effects. In fact, Serzone at times may act similarly to Wellbutrin in its neutral or at times positive effect on function. It has been discontinued in several countries due to rare cases of liver failure. The tradename "Serzone®" has been discontinued, however generic nefazodone is currently available (May 06). However, the liver failure is rare, and a simple blood test every 6 months to assess liver enzyme levels is sufficient. Nefazodone has an active metabolite which at higher doses (> 250mg/day) can increase anxiety. One of the benefits nefazodone has over Effexor® and Cymbalta® is its enhanced sedation when taken at bedtime.
  • milnacipran (tradename Dalcipran®/ Portugal; Ixel®/ France) has shown to be significantly effective in the treatment of depression and Fibromyalgia syndrome (FMS). Although it has not yet been approved by the Food and Drug Administration (FDA) for use in the United States, it has been commercially available in Europe and Asia for several years.
  • desipramine (tradenames Norpramine®, Pertofraneis®) is technically a tricyclic antidepressant, and is usually categorized as such. It works, however, on both serotonin and norepinephrine, so it can also be considered an SNRI.
  • duloxetine (tradename Cymbalta®) by Eli Lilly and Company, also inhibits serotonin reuptake and has been approved for the treatment of depression and neuropathic pain in August of 2004.

Please note that some of the above medications may not be considered "true" SNRIs; refer to specific peer-reviewed scientific journals for more in-depth coverage on classifications and pharmaco-kinetics.

See also


Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg